2-FUROYL-LEU-ILE-GLY-ARG-LEU-ORN-NH2
2-FUROYL-LEU-ILE-GLY-ARG-LEU-ORN-NH2
2-FUROYL-LEU-ILE-GLY-ARG-LEU-ORN-NH2 性质
| 密度 | 1.33±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | -20°C |
| 溶解度 | 溶于H2O |
| 形态 | 粉末 |
| 酸度系数(pKa) | 12.91±0.46(Predicted) |
| 颜色 | 白色 |
| 水溶解性 | Soluble to 1 mg/ml in water |
| InChI | 1S/C17H16ClN3OS/c1-9-7-10(2)21-17-13(9)14(19)15(23-17)16(22)20-8-11-3-5-12(18)6-4-11/h3-7H,8,19H2,1-2H3,(H,20,22) |
| InChIKey | FPRULFHDSFKYBV-UHFFFAOYSA-N |
| SMILES | Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc3ccc(Cl)cc3 |
2-FUROYL-LEU-ILE-GLY-ARG-LEU-ORN-NH2 用途与合成方法
Proteinase-activated receptor 2 (PAR2)
2-Furoyl-LIGRLO-amide (2-Furoyl-LIGRLO-NH
2
) is equally effective to and 10 to 25 times more potent than SLIGRLNH
2
for increasing intracellular calcium in cultured human and rat PAR2-expressing cells, respectively.
In bioassays of tissue PAR2 activity, measured as arterial vasodilation and hyperpolarization, 2-Furoyl-LIGRLO-amide (2-Furoyl-LIGRLO-NH
2
) is 10 to 300 times more potent than SLIGRL-NH
2
. Unlike trans-cinnamoyl-LIGRLO-NH
2
, 2-Furoyl-LIGRLO-amide do not cause a prominent non-PAR2-mediated contraction of murine femoral arteries.
Furoyl-LIGRLO-amide (injected intradermally at the nape of the neck; 10 μg; pre-injected) exhibits fewer scratches in response to 2-Furoyl-LIGRLO-amide but not to histamine in Trpv3 -/- mice. But it decreases significantly the number of scratches in WT mice.
| Animal Model: | Adult male (2/3-month-old) Trpv3 -/- and WT mice |
| Dosage: | 10 μg |
| Administration: | Injected intradermally at the nape of the neck |
| Result: | Was involved in PAR2- induced acute itch. |
2-FUROYL-LEU-ILE-GLY-ARG-LEU-ORN-NH2 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-P1314 | 2-FUROYL-LEU-ILE-GLY-ARG-LEU-ORN-NH2 | 729589-58-6 | 1mg | 990 |
| 2026-09-15 | HY-P1314 | 2-FUROYL-LEU-ILE-GLY-ARG-LEU-ORN-NH2 | 729589-58-6 | 5mg | 2500 |
